收藏切换
Application of nafamostat mesylate in hyperbilirubinemia patients with hepatic failure treated by artificial liver support system
收藏切换
Yue GUO, Lianxiang DUAN, Wenrui LIU, Ziyang LIU, Jianrao LU, Jing HU*
World Clinical Drug | 2024, 45(4) : 397 - 402
Less
收藏切换
World Clinical Drug | 2024, 45(4): 397-402
• Article •
Application of nafamostat mesylate in hyperbilirubinemia patients with hepatic failure treated by artificial liver support system
Full
Yue GUO, Lianxiang DUAN, Wenrui LIU, Ziyang LIU, Jianrao LU, Jing HU*
Affiliations
  • Department of Nephrology, Shanghai Seventh People's Hospital, Shanghai 200137, China
Published: 2024-04-10 doi: 10.13683/j.wph.2024.04.009
Outline
收藏切换
Objective

To evaluate the efficacy and safety of nafamostat mesylate (NM) in hyperbilirubinemia patients with hepatic failure (HF) treated with artificial liver support system (ALSS).

Methods

A total of 54 HF patients who received ALSS in our hospital from September 2020 to March 2023 were selected, of which 28 were treated with NM anticoagulation and 26 were treated with low molecular weight heparin (LMWH). All patients received two treatments, each lasting 3 hours. Hemodialyzer coagulation, bleeding complications, adverse reactions, total bilirubin (TBil) reduction rate, 30, 90 days survival rate were observed and measured.

Results

There was no significant difference in blood flow rate between the two groups (P>0.05). After treatment, there was no significant difference in the reduction rate of TBil in the NM group compared with the LMWH group [(60.43±6.29)% vs (61.27%±6.45)%, P>0.05]. There were no significant differences in dialyzer coagulation, red blood cell transfusion, hypotension, 30, 90 days survival rate and nausea and vomiting between the two groups (P>0.05). There was no gastrointestinal bleeding in the NM group, and 4 cases in the LMWH group, the difference was statistically significant (P<0.05).

Conclusion

Compared with LMWH, NM does not increase the risk of bleeding in HF patients undergoing ALSS, and is a safe and effective anticoagulant.

nafamostat mesylate  /  artificial liver support system  /  hepatic failure  /  hyperbilirubinemia  /  low molecular weight heparin  /  anticoagulant
郭玥, 段连香, 刘文瑞, 刘子洋, 路建饶, 胡静. 甲磺酸萘莫司他在行人工肝支持系统治疗的肝衰竭高胆红素血症患者中的应用. 世界临床药物, 2024 , 45 (4) : 397 -402 . DOI: 10.13683/j.wph.2024.04.009
Yue GUO, Lianxiang DUAN, Wenrui LIU, Ziyang LIU, Jianrao LU, Jing HU. Application of nafamostat mesylate in hyperbilirubinemia patients with hepatic failure treated by artificial liver support system[J]. World Clinical Drug, 2024 , 45 (4) : 397 -402 . DOI: 10.13683/j.wph.2024.04.009
Year 2024 volume 45 Issue 4
16
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2024.04.009
  • Receive Date:2024-01-10
  • Online Date:2026-11-17
  • Published:2024-04-10
Article Data
Affiliations
History
  • Received:2024-01-10
Funding
Affiliations
    Department of Nephrology, Shanghai Seventh People's Hospital, Shanghai 200137, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2024.04.009
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT